Short Summary
Activision Blizzard has filed an IPR petition challenging Milestone Entertainment’s ’336 gaming patent, asserting obviousness over Kelly683 and over Walker combined with Schneier143. The petition seeks institution and a finding of unpatentability for 19 claims.
Detailed Summary
In a petition for inter partes review (IPR2025-0708), Activision Blizzard challenges U.S. Patent No. 8,529,336 owned by Milestone Entertainment. The challenger contends that the patent’s method claims, covering electronic interaction, mandated and variable parameters, and related gaming features, are obvious in view of the Kelly683 system alone and the combination of Walker with Schneier143. The petition details how each claim limitation is disclosed in the prior art, argues that no secondary considerations exist, and requests the Board to institute the review and deem all 19 challenged claims unpatentable.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Activision Blizzard, Inc. vs Milestone Entertainment, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLCvsCellular South Inc
The PTAB denied Google's request to institute IPR against Cellular South's patent (11,126,853), finding the petitioner failed to establish a reasonable likelihood of success on obviousness grounds.
Samsung Electronics Co., Ltd. et al.vsOne-E-Way, Inc.
The USPTO granted institution for IPR2025-01541 after determining the petitioner had a reasonable likelihood of prevailing. This decision moves the case forward to merits review.
Snap Inc. et al.vsNokia Technologies Oy
Nokia and Hisense have settled their dispute over a video‑capable device patent and jointly moved to terminate the inter partes review as to Hisense. The motion invokes 35 U.S.C. §317 and requests confidentiality for the settlement documents.
Quotient Technology, LLC et al.vsIntelligent Clearing Network Inc. et al.
The PTAB terminated IPR2024-01324 (patent 9,098,855) after Quotient Technology and Intelligent Clearing Network reached a settlement, filing a joint motion to end the review.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed an IPR petition challenging Halozyme’s ’656 patent covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description and enablement and that US‑275 anticipates all claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.